Cargando…

In vitro models for head and neck cancer: Current status and future perspective

The 5-year overall survival rate remains approximately 50% for head and neck (H&N) cancer patients, even though new cancer drugs have been approved for clinical use since 2016. Cancer drug studies are now moving toward the use of three-dimensional culture models for better emulating the unique t...

Descripción completa

Detalles Bibliográficos
Autores principales: Moya-Garcia, Christian R., Okuyama, Hideaki, Sadeghi, Nader, Li, Jianyu, Tabrizian, Maryam, Li-Jessen, Nicole Y. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381731/
https://www.ncbi.nlm.nih.gov/pubmed/35992863
http://dx.doi.org/10.3389/fonc.2022.960340
_version_ 1784769138614337536
author Moya-Garcia, Christian R.
Okuyama, Hideaki
Sadeghi, Nader
Li, Jianyu
Tabrizian, Maryam
Li-Jessen, Nicole Y. K.
author_facet Moya-Garcia, Christian R.
Okuyama, Hideaki
Sadeghi, Nader
Li, Jianyu
Tabrizian, Maryam
Li-Jessen, Nicole Y. K.
author_sort Moya-Garcia, Christian R.
collection PubMed
description The 5-year overall survival rate remains approximately 50% for head and neck (H&N) cancer patients, even though new cancer drugs have been approved for clinical use since 2016. Cancer drug studies are now moving toward the use of three-dimensional culture models for better emulating the unique tumor microenvironment (TME) and better predicting in vivo response to cancer treatments. Distinctive TME features, such as tumor geometry, heterogenous cellularity, and hypoxic cues, notably affect tissue aggressiveness and drug resistance. However, these features have not been fully incorporated into in vitro H&N cancer models. This review paper aims to provide a scholarly assessment of the designs, contributions, and limitations of in vitro models in H&N cancer drug research. We first review the TME features of H&N cancer that are most relevant to in vitro drug evaluation. We then evaluate a selection of advanced culture models, namely, spheroids, organotypic models, and microfluidic chips, in their applications for H&N cancer drug research. Lastly, we propose future opportunities of in vitro H&N cancer research in the prospects of high-throughput drug screening and patient-specific drug evaluation.
format Online
Article
Text
id pubmed-9381731
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93817312022-08-18 In vitro models for head and neck cancer: Current status and future perspective Moya-Garcia, Christian R. Okuyama, Hideaki Sadeghi, Nader Li, Jianyu Tabrizian, Maryam Li-Jessen, Nicole Y. K. Front Oncol Oncology The 5-year overall survival rate remains approximately 50% for head and neck (H&N) cancer patients, even though new cancer drugs have been approved for clinical use since 2016. Cancer drug studies are now moving toward the use of three-dimensional culture models for better emulating the unique tumor microenvironment (TME) and better predicting in vivo response to cancer treatments. Distinctive TME features, such as tumor geometry, heterogenous cellularity, and hypoxic cues, notably affect tissue aggressiveness and drug resistance. However, these features have not been fully incorporated into in vitro H&N cancer models. This review paper aims to provide a scholarly assessment of the designs, contributions, and limitations of in vitro models in H&N cancer drug research. We first review the TME features of H&N cancer that are most relevant to in vitro drug evaluation. We then evaluate a selection of advanced culture models, namely, spheroids, organotypic models, and microfluidic chips, in their applications for H&N cancer drug research. Lastly, we propose future opportunities of in vitro H&N cancer research in the prospects of high-throughput drug screening and patient-specific drug evaluation. Frontiers Media S.A. 2022-08-03 /pmc/articles/PMC9381731/ /pubmed/35992863 http://dx.doi.org/10.3389/fonc.2022.960340 Text en Copyright © 2022 Moya-Garcia, Okuyama, Sadeghi, Li, Tabrizian and Li-Jessen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Moya-Garcia, Christian R.
Okuyama, Hideaki
Sadeghi, Nader
Li, Jianyu
Tabrizian, Maryam
Li-Jessen, Nicole Y. K.
In vitro models for head and neck cancer: Current status and future perspective
title In vitro models for head and neck cancer: Current status and future perspective
title_full In vitro models for head and neck cancer: Current status and future perspective
title_fullStr In vitro models for head and neck cancer: Current status and future perspective
title_full_unstemmed In vitro models for head and neck cancer: Current status and future perspective
title_short In vitro models for head and neck cancer: Current status and future perspective
title_sort in vitro models for head and neck cancer: current status and future perspective
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381731/
https://www.ncbi.nlm.nih.gov/pubmed/35992863
http://dx.doi.org/10.3389/fonc.2022.960340
work_keys_str_mv AT moyagarciachristianr invitromodelsforheadandneckcancercurrentstatusandfutureperspective
AT okuyamahideaki invitromodelsforheadandneckcancercurrentstatusandfutureperspective
AT sadeghinader invitromodelsforheadandneckcancercurrentstatusandfutureperspective
AT lijianyu invitromodelsforheadandneckcancercurrentstatusandfutureperspective
AT tabrizianmaryam invitromodelsforheadandneckcancercurrentstatusandfutureperspective
AT lijessennicoleyk invitromodelsforheadandneckcancercurrentstatusandfutureperspective